Extensive studies in recent years have shown that dysregulation of GSK3β is a key event that contributes to the development and progression of several neurological disorders, and inhibitors of GSK3β have been shown to be beneficial in many neuroinflammatory disease models including Alzheimer’s disease, multiple sclerosis and AIDS dementia complex (reviewed in [61]. The gene discussed is GSK3B; the disease is early-onset autosomal dominant Alzheimer disease.